Health-related quality of life in cancer immunotherapy: a systematic perspective, using causal loop diagrams

被引:13
作者
Beaulieu, Elizabeth [1 ]
Spanjaart, Anne [2 ]
Roes, Ashley [1 ]
Rachet, Bernard [3 ]
Dalle, Stephane [4 ]
Kersten, Marie Jose [2 ]
Maucort-Boulch, Delphine [5 ]
Jalali, Mohammad S. [1 ,6 ]
机构
[1] Harvard Med Sch, MGH Inst Technol Assessment, Boston, MA 02115 USA
[2] Univ Amsterdam, Canc Ctr Amsterdam, Dept Hematol, Amsterdam UMC, Amsterdam, Netherlands
[3] London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London, England
[4] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Dermatol, Pierre Benite, France
[5] Hosp Civils Lyon, Dept Biostat, Lyon, France
[6] MIT, Sloan Sch Management, 77 Massachusetts Ave, Cambridge, MA 02139 USA
关键词
Immunotherapy; Cancer; Quality of life; Systems science; END-POINTS; OUTCOMES; LYMPHEDEMA; IMPACT; DRUG;
D O I
10.1007/s11136-022-03110-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose System science offers a unique set of tools, including causal loop diagrams (CLDs), for stakeholders to better grasp the complexity of factors surrounding quality of life. Because the health-related quality of life (HRQoL) of cancer immunotherapy patients exists within an intricate system affected by and affecting many factors across multiple dimensions, the development of a systems-level model can provide a powerful framework to aid the understanding of this complexity. We developed a CLD for HRQoL of cancer immunotherapy patients. Methods We first applied a literature-based approach to construct a CLD for patients following immunotherapy. We then iteratively reviewed and enhanced the CLD through interviews with subject matter experts. Results Based on the reviewed literature and subject matter expert input, we produced a CLD representing the system surrounding cancer immunotherapy patients' HRQoL. Several feedback loops are identified that span clinical experiences, oncology teams' perceptions about immunotherapy, social support structures, and further research and development in cancer immunotherapy, in addition to other components. The CLD enables visualization of thought experiments regarding how a change anywhere in the system can ultimately worsen or improve patients' HRQoL. Conclusion The CLD illustrates the valuable contribution of a systems perspective to quality-of-life research. This systems-based qualitative representation gives insight on strategies to inhibit harmful effects, enhance beneficial effects, and inherent tradeoffs within the system. The CLD identifies gaps in the literature and offers a communication tool for diverse stakeholders. Our research method provides an example for studying the complexities of quality of life in other health domains.
引用
收藏
页码:2357 / 2366
页数:10
相关论文
共 67 条
[51]   Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group [J].
Puzanov, I. ;
Diab, A. ;
Abdallah, K. ;
Bingham, C. O., III ;
Brogdon, C. ;
Dadu, R. ;
Hamad, L. ;
Kim, S. ;
Lacouture, M. E. ;
LeBoeuf, N. R. ;
Lenihan, D. ;
Onofrei, C. ;
Shannon, V. ;
Sharma, R. ;
Silk, A. W. ;
Skondra, D. ;
Suarez-Almazor, M. E. ;
Wang, Y. ;
Wiley, K. ;
Kaufman, H. L. ;
Ernstoff, M. S. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[52]   A follow-up study of the quality of life in cancer patients with different prognoses [J].
Ringdal, GI ;
Ringdal, K .
QUALITY OF LIFE RESEARCH, 2000, 9 (01) :65-73
[53]   System dynamics of cancer in erythropoiesis with multiple EPO feedbacks [J].
Sajid, Zamra ;
Andersen, Morten ;
Ottesen, Johnny T. .
SYSTEM DYNAMICS REVIEW, 2020, 36 (04) :447-466
[54]   Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group [J].
Spanjaart, Anne Mea ;
Ljungman, Per ;
de La Camara, Rafael ;
Tridello, Gloria ;
Ortiz-Maldonado, Valentin ;
Urbano-Ispizua, Alvaro ;
Barba, Pere ;
Kwon, Mi ;
Caballero, Dolores ;
Sesques, Pierre ;
Bachy, Emmanuel ;
Di Blasi, Roberta ;
Thieblemont, Catherine ;
Calkoen, Friso ;
Mutsaers, Pim ;
Maertens, Johan ;
Giannoni, Livia ;
Nicholson, Emma ;
Collin, Matthew ;
Vaz, Carlos Pinho ;
Metafuni, Elisabetta ;
Martinez-Lopez, Joaquin ;
Dignan, Fiona L. ;
Ribera, Josep-Maria ;
Nagler, Arnon ;
Folber, Frantisek ;
Sanderson, Robin ;
Bloor, Adrian ;
Ciceri, Fabio ;
Knelange, Nina ;
Ayuk, Francis ;
Kroger, Nicolaus ;
Kersten, Marie Jose ;
Mielke, Stephan .
LEUKEMIA, 2021, 35 (12) :3585-3588
[55]   Disparity in Perceptions of Disease Characteristics, Treatment Effectiveness, and Factors Influencing Treatment Adherence Between Physicians and Patients With Myelodysplastic Syndromes [J].
Steensma, David P. ;
Komrokji, Rami S. ;
Stone, Richard M. ;
List, Alan F. ;
Garcia-Manero, Guillermo ;
Huber, John M. ;
Dennison, Betsy ;
Sekeres, Mikkael A. .
CANCER, 2014, 120 (11) :1670-1676
[56]   Learning from evidence in a complex world [J].
Sterman, JD .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2006, 96 (03) :505-514
[57]   Cancer-treatment-induced neurotoxicity - focus on newer treatments [J].
Stone, Jacqueline B. ;
DeAngelis, Lisa M. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (02) :92-105
[58]   Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease [J].
Taarnhoj, Gry A. ;
Johansen, Christoffer ;
Lindberg, Henriette ;
Basch, Ethan ;
Dueck, Amylou ;
Pappot, Helle .
CANCER MEDICINE, 2020, 9 (09) :3078-3087
[59]   Lymphedema following breast cancer treatment and impact on quality of life: A review [J].
Taghian, Nadine R. ;
Miller, Cynthia L. ;
Jamrnallo, Lauren S. ;
O'Toole, Jean ;
Skolny, Melissa N. .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2014, 92 (03) :227-234
[60]   Quality of Life After Radical Cystectomy [J].
Tyson, Mark D., II ;
Barocas, Daniel A. .
UROLOGIC CLINICS OF NORTH AMERICA, 2018, 45 (02) :249-+